Publication: The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer
No Thumbnail Available
Open/View Files
Date
2010-07
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier BV
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Sasaki, Takaaki, Scott Rodig, Lucian Chirieac, Pasi Janne. "The Biology and Treatment of EML4-ALK Non-Small Cell Lung Cancer." European Journal of Cancer 46, no. 10 (2010): 1773-1780. DOI: 10.1016/j.ejca.2010.04.002
Research Data
Abstract
The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.
Description
Other Available Sources
Keywords
Research Subject Categories::MEDICINE::Morphology, cell biology, pathology::Morphology::Tumour biology, Research Subject Categories::MEDICINE::Surgery::Oncology
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service